Edwards Lifesciences Corporation (NYSE:EW) Shares Sold by Hartford Investment Management Co.

Hartford Investment Management Co. reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 1.0% during the 1st quarter, HoldingsChannel.com reports. The firm owned 36,067 shares of the medical research company’s stock after selling 372 shares during the quarter. Hartford Investment Management Co.’s holdings in Edwards Lifesciences were worth $2,614,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of EW. Brighton Jones LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $266,000. Bank Pictet & Cie Europe AG lifted its stake in shares of Edwards Lifesciences by 16.7% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company’s stock valued at $757,000 after purchasing an additional 1,463 shares in the last quarter. Schroder Investment Management Group acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $7,176,000. Arete Wealth Advisors LLC lifted its position in Edwards Lifesciences by 20.4% during the 4th quarter. Arete Wealth Advisors LLC now owns 4,139 shares of the medical research company’s stock worth $307,000 after acquiring an additional 700 shares in the last quarter. Finally, ExodusPoint Capital Management LP acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $2,253,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $79.30 on Friday. Edwards Lifesciences Corporation has a twelve month low of $59.41 and a twelve month high of $83.00. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $46.52 billion, a price-to-earnings ratio of 11.41, a price-to-earnings-growth ratio of 3.84 and a beta of 1.08. The business has a 50 day simple moving average of $76.91 and a 200-day simple moving average of $73.82.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.25% and a net margin of 72.96%. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the business earned $0.70 EPS. The business’s quarterly revenue was up 11.9% on a year-over-year basis. As a group, equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Daiwa America raised Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Evercore ISI boosted their price target on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an “in-line” rating in a research report on Friday, July 25th. Wall Street Zen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Barclays boosted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. Finally, JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, July 25th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus price target of $85.71.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the completion of the sale, the chief financial officer owned 41,098 shares of the company’s stock, valued at $3,057,691.20. This trade represents a 21.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,962 shares of company stock worth $2,641,387. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.